Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenascin-C siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intravitreal, Intratumoral
01
Overview
Tenascin-C siRNA is an experimental research compound belonging to the class of small interfering RNAs (siRNAs). It is designed to silence the expression of **tenascin-C (TNC)**, a large hexameric extracellular matrix glycoprotein that is typically absent or low in adult tissues but highly upregulated during inflammation, wound healing, and tumorigenesis. By binding to and promoting the degradation of TNC mRNA through the RNA interference (RNAi) pathway, this agent reduces the levels of TNC protein. Preclinical studies have investigated its utility in various pathological contexts, including **Duchenne muscular dystrophy (DMD)** to restore sodium currents and improve cardiac conduction, **choroidal neovascularization** in age-related macular degeneration, and the inhibition of tumor growth and metastasis in cancers such as **glioma** and **gastric cancer**. It is currently utilized as a generic experimental reagent across multiple independent academic research programs rather than as a single proprietary clinical asset.
- Other names
- TNC siRNAtenascin-C small interfering RNA
02
Targets
TNC (Tenascin-C fibronectin type III domains)
Beyond the preview
Go deeper on tenascin-C siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenascin-C siRNA.